For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Daiichi Sankyo to Integrate Global, Japan Business Management Functions into Four-Division Structure
March 8, 2012
-
ORGANIZATION Wholesale Industry FTC to “Watch Closely” How Drug Makers Respond to Tougher Rules on Business Entertaining
March 7, 2012
-
BUSINESS Eisai to See 11%+, Lilly Japan 8-9% Average Price Reduction in FY2012 NHI Price Revision: Jiho Survey
March 6, 2012
-
REGULATORY 702 Products Including DPP-4 Inhibitors to Be Eligible for New Drug Premium in April
March 5, 2012
-
REGULATORY Private-Sector Members of Strategy Council Call for Early Establishment of Drug Discovery Support Organization
March 5, 2012
-
ORGANIZATION KSLION to Stimulate Innovation in Life Science in Japan: Prof. Y. Natsumeda
March 5, 2012
-
BUSINESS Medipal Group to Determine Profitability with Each Customer: Next President Shuichi Watanabe
March 2, 2012
-
BUSINESS DSP to Acquire Boston Biomedical, US Bioventure Specializing in Oncology
March 1, 2012
-
BUSINESS Pfizer Japan to Set Up Rare Disease Division
February 29, 2012
-
REGULATORY MHLW Conducts Hearing on Distribution Improvement with Drug Manufacturers
February 28, 2012
-
REGULATORY Next 5-Year Strategy Calls for Boost to Japanese“Rising Sun”Seed Development
February 27, 2012
-
REGULATORY PAFSC’s First Committee on Drugs Recommends Approval for Eli Lilly’s Once-Weekly GLP-1 Receptor Agonist
February 27, 2012
-
BUSINESS Diabetes Treatments: Their Development and Market (2)
February 27, 2012
-
BUSINESS Daiichi Sankyo and Terumo Codevelop Intradermal Vaccine
February 24, 2012
-
REGULATORY MEXT to Make Drug Education Compulsory at Junior High Schools from FY2012
February 23, 2012
-
BUSINESS Novo Nordisk President Says “Current Pipeline Most Substantial”
February 22, 2012
-
ORGANIZATION Japan Pharmaceutical Political Association Chairman Kumakura to Focus on Resolving Price Difference
February 21, 2012
-
REGULATORY MHLW Issues Improvement Order to Janssen Pharmaceutical for GMP Violation
February 20, 2012
-
BUSINESS Diabetes Treatments: Their Development and Market
February 20, 2012
-
BUSINESS 6 SGLT-2 Inhibitors in Final Development Stage, Applications Expected in 2013
February 17, 2012
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…